Diabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032 [Yahoo! Finance]
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: Yahoo! Finance
Key Highlights In the 7MM, the United States accounted for the largest market size in 2022, with approximately USD 6,200 million. The disease is reported to occur in 20-50% of those living with diabetes and is the single most common cause of end-stage kidney disease (ESKD) in many populations. Current management strategies employ aggressive glycemic and blood pressure control combined with renin-angiotensin-aldosterone system-blocking agents to slow the worsening of kidney disease. For a long time, there were no drugs specific to DKD other than RAS inhibitors. In 2019, a CREDENCE trial proved the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for DKD, adding a new treatment option. INVOKANA and FARXIGA are two of the approved SGLT2 inhibitors available in the US, Europe, and Japan for treating DKD. Moreover, recently, JARDIANCE has also gained approval in the US and Europe in 2023 for treating CKD patients with and without type-2 diabetes. Among novel treat
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- ProKidney Reports Business Updates and First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- ProKidney Reports Business Updates and First Quarter 2024 Financial ResultsGlobeNewswire
- Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers [Seeking Alpha]Seeking Alpha
- Diabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
PROK
Earnings
- 5/10/24 - Beat
PROK
Sec Filings
- 5/10/24 - Form 10-Q
- 5/10/24 - Form 8-K
- 4/26/24 - Form ARS
- PROK's page on the SEC website